A diabetes drug has been approved by a UK regulator to help obese and overweight adults lose weight.
Patients with weight-related health problems – such as prediabetes, high blood pressure, high cholesterol or heart problems – will have access to the drug Mounjaro privately after it was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
It needs further approval from the National Institute for Health and Care Excellence (NICE) to be made available on the NHS.
Health Secretary Steve Barclay said: “Although further approvals are needed to use this in the NHS, Mounjaro has the potential to help thousands of people living with obesity and support those suffering from weight-related illnesses – if used alongside diet and physical activity.
“Tackling obesity could help cut waiting lists and save the NHS billions of pounds.”
Explainer: Ozempic to Wegovy – what are the weight loss injections and what were they designed to do?
The active ingredient in the drug – tirzepatide – works by making a patient feel full and less hungry, and making them experience fewer food cravings.
The MHRA’s authorisation is based on the results of two clinical trials, one of which showed patients who received the highest dose of the drug lost 22.5% of their body weight over a 72-week period.
The second showed patients with Type-2 diabetes lost 15.7% of their body weight over 72 weeks.
The trials showed patients treated with Mounjaro “had a significant weight loss over time compared to patients who took a placebo”.
The agency listed the potential side effects of the medicine, including nausea, diarrhoea, vomiting – which usually goes away over time – and constipation.
Low blood sugar is also “very common” in patients with diabetes, it added.
It also warned the drug may affect how well the contraceptive pill works in obese or overweight female patients.
Read more:
Weight loss drugs investigated over suicidal thoughts
Next wave of weight-loss jabs could be coming
Julian Beach, MHRA interim executive director, healthcare quality and access, said: “We have prioritised rapid assessment of this new indication for Mounjaro, given the public health importance of access to new medicines to help tackle obesity.
“We have drawn on advice from the independent Commission on Human Medicines in coming to our decision, and as with all products, will keep the safety of Mounjaro under close review.”
The MHRA said it will keep the safety and effectiveness of Mounjaro under close review.
In September weight-loss jab Wegovy was launched in the UK to help tackle obesity.
The drug was approved for NHS use by NICE earlier this year and is now available to patients via specialist services.
